Ergoferon lozenges, No. 20

Ergoferon is indicated for use in adults and children aged 6 months.

• treatment of influenza and ARVI;

• treatment of acute intestinal infections of viral etiology.

Inside. At one time - 1 table. (not during meals). The tablet should be kept in the mouth without swallowing until it is completely dissolved.

Children from 6 months When prescribing the drug to young children (from 6 months to 3 years), it is recommended to dissolve the tablet in a small amount (1 tablespoon) of boiled water at room temperature.

Treatment should be started as early as possible, when the first signs of an acute infection appear, according to the following scheme: in the first 2 hours, the drug is taken every 30 minutes, then during the first day, 3 more doses are taken at regular intervals. From 2 days onwards, take 1 table. 3 times a day until complete recovery.

For the prevention of viral infectious diseases - 1-2 table. in a day. The recommended duration of the prophylactic course is determined individually and can be 1Ц6 months.

If necessary, the drug can be combined with other antiviral and symptomatic agents.

Lozenges from white to almost white, flat-cylindrical shape, with a score and a bevel; the flat side with scribble has the inscription MATERIA MEDICA, the other flat side has the inscription ERGOFERON.

1 tab.

antibodies to human gamma interferon affinity purified 0.006 g *

antibodies to histamine affinity purified 0.006 g *

antibodies to CD4 affinity purified 0.006 g *

* applied to lactose monohydrate in the form of a mixture of three active aqueous-alcoholic dilutions of the substance, diluted 10012, 10030, 10050 times, respectively.

Excipients: lactose monohydrate - 0.267 g, microcrystalline cellulose - 0.03 g, magnesium stearate - 0.003 g.

• Children up to age 6 months;

• lactase deficiency, lactose intolerance, glucose-galactose malabsorption;

• increased individual sensitivity to the components of the drug.

pharmachologic effect

The spectrum of pharmacological activity of the drug Ergoferon includes antiviral, immunomodulatory, antihistamine, anti-inflammatory.

The components included in the drug have a single mechanism of action in the form of an increase in the functional activity of the CD4 receptor, receptors for interferon gamma (IFN-?) and histamine, respectively, which is accompanied by a pronounced immunotropic effect.

It has been experimentally proven that antibodies to interferon gamma increase the expression of IFN-?, IFN-? / ?, as well as interleukins conjugated with them (IL-2, IL-4, IL-10 and others), improve the ligand-receptor interaction of IFN, restore cytokine status; normalize the concentration and functional activity of natural antibodies to IFN-?, which are an important factor in the body's natural antiviral tolerance; stimulate interferon-dependent biological processes (induction of expression of antigens of the main histocompatibility complex of types I, II and Fc receptors, activation of monocytes, stimulation of the functional activity of NK cells, regulation of immunoglobulin synthesis, activating a mixed Th1 and Th2 immune response).

Antibodies to CD4, probably being allosteric modulators of this receptor, regulate the functional activity of the CD4 receptor, which leads to an increase in the functional activity of CD4 lymphocytes, normalization of the CD4 / CD8 immunoregulatory index, as well as the subpopulation composition of immunocompetent cells (CD3, CD4, CD8, CD16, CD20).

Antibodies to histamine modify the histamine-dependent activation of peripheral and central H1 receptors and, thus, reduce the tone of smooth muscles of the bronchi, reduce capillary permeability, which leads to a reduction in the duration and severity of rhinorrhea, swelling of the nasal mucosa, coughing and sneezing, as well as a decrease in the severity of allergic reactions accompanying the infectious process due to the suppression of the release of histamine from mast cells and basophils, the production of leukotrienes, the synthesis of adhesion molecules, a decrease in eosinophil chemotaxis and platelet aggregation in reactions to contact with an allergen.

The combined use of the components of the complex preparation is accompanied by an increase in the antiviral activity of its constituent components.

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, gas chromatography-mass spectrometry) does not allow assessing the content of active components of Ergoferon in biological fluids, organs and tissues, which makes it technically impossible to study pharmacokinetics.

Side effect

Possible reactions of increased individual sensitivity to the components of the drug.

Application during pregnancy and lactation

The safety of using Ergoferon during pregnancy has not been studied.

During pregnancy and lactation, the drug is used only if the intended benefit to the mother outweighs the potential risk to the fetus and child. The benefit / risk ratio is determined by the attending physician.

Application in children

The use of the drug is contraindicated in children under 6 months of age.

special instructions

The drug contains lactose monohydrate, and therefore it is not recommended to prescribe it to patients with congenital galactosemia, glucose or galactose malabsorption syndrome, or congenital lactase deficiency.

Influence on the ability to drive vehicles and mechanisms

Ergoferon does not affect the ability to drive vehicles and other potentially dangerous mechanisms.

Overdose

In case of an accidental overdose, dyspeptic phenomena are possible due to the fillers included in the preparation.

Drug interactions

To date, no cases of incompatibility with other drugs have been registered.